Lightstone Ventures’ Post

Are you looking to streamline your clinical trial? With over 25 years of clinical research expertise, Clinical Research Advancement offers a unique and advanced model for your clinical trial needs. Our Global Services include: Study Startup, Site Identification, Patient Recruitment and Retention, Decentralized Trial Support, and more! cradvancement.com | tobempowered.com #ClinicalResearch #GlobalCRO #CRO #ClinicalTrials #Biotech #ClinicalProjectManagement #GlobalContractResearchOrganization #PatientRecruitmentServices #PharmaceuticalResearch #ContractResearchOrganization #ClinicalTrialManagement #DrugDevelopment #DecentralizedClinicalTrials #APAC #MiddleEast #Africa #Oncology #Thoracic #HepatocellularCarcinoma #MedTech #PopulationScience #HealthEquity

Drug development in early phase non-oncology clinical studies has undergone significant changes in recent years. In our latest white paper, IQVIA’s H. David Duque, MD, CPI and Liz Allen explore the factors that have driven these changes, analyze their impact on the design and execution of these studies, and examine the challenges facing clinical researchers today. Download now. https://bit.ly/3t4BxRn #drugdevelopment #oncology

Cure GM1 provided funding to initiate this project. See the exciting news below of how our funding resulted in more funding! curegm1.org/donate Since 2019, there have been 4 clinical trials and 33 participants in the trials (This is a lot for an ultra-rare disease). This project and others are geared towards the future and having an arsenal of approches for a complex and truly devastating disease. From TEGA: TEGA Therapeutics, Inc. has been awarded a Phase I Small Business and Innovative Research (SBIR) grant ($461,701) from the National Institute of Neural Disorders and Stroke (NINDS) for the project “Development and Validation of Therapy for GM1 Gangliosidosis”. The award will fund preclinical research, administering enzyme replacement therapy directly to the brain for treating the neurological effects of GM1 gangliosidosis. With successful completion of the Phase I grant, TEGA will apply for a Phase II SBIR grant, which could potentially fund in the multimillion-dollar range to help advance the program to human clinical trials. #curegm1 #hope #raredisease #donate #give #fightforlife

📢 Exciting news in the world of oncology! The US FDA has approved Ogsiveo (nirogacestat) tablets, the first-ever drug for treating adult patients with progressing desmoid tumors. These rare, non-cancerous, but locally aggressive tumors can invade surrounding structures and organs, causing pain, mobility issues, and decreased quality of life. 🎗 ↪ Historically, surgical removal has been the primary treatment, but the risk of recurrence and other health complications post-surgery has led to an increased focus on systemic therapies. 💉 💊 The approval of Ogsiveo is a significant step forward in addressing the unmet medical needs of patients with rare tumors. The drug demonstrated clinically meaningful and statistically significant improvement in progression-free survival compared to placebo in a pivotal clinical trial. 💯 🌈 The FDA granted Ogsiveo with Priority Review, Fast Track, Breakthrough Therapy, and Orphan-Drug designations. 💪 👏 Congratulations to SpringWorks Therapeutics Inc. on this remarkable achievement! 🙌 👉 For more information on this update, check out the link - https://lnkd.in/dsebtJPj #fda #approval #oncology #desmoidtumors #rarediseases #medicalbreakthroughs

Calyx scientists routinely leverage their broad expertise in #CNS drug development to manage the #MedicalImaging components of #neuro-oncology clinical trials effectively and efficiently. Learn more. https://lnkd.in/e-r-FbkT #clinicaltrials #oncology #ChooseCalyx #MedicalImaging #clinicaltrials #clinicalresearch #Calyx

#Tagraxofusp: the first #CD123-targetedagent in oncology and the first grug specifically approved for #blasticplasmacytoiddendriticcellneoplasm. Read the new review on its development, key preclinical insights, clinical data, and its unique toxicity, the capillary leak syndrome. https://lnkd.in/dsjNx6X3

Engrail Therapeutics closes a robust Series B funding round, bolstering its neuropsychiatric pipeline. Led by F-Prime Capital, Forbion, and Norwest Venture Partners, the oversubscribed round extends Engrail's financial runway to mid-2026. CEO Vikram Sudarsan anticipates advancing ENX-102's phase 2 trial for generalized anxiety, targeting topline data by H1 2025. The funding also accelerates preclinical molecules ENX-104 and ENX-105 towards clinical development. With investor confidence high, Engrail aims for impactful strides in treating mental health disorders.

Why is prioritization in clinical trials a game-changer? 🤔 Join an interactive Roundtable Discussion on “Optimizing Resource Allocation: Why Prioritization Matters in Clinical Trial?” at our Upcoming Conference in Boston, on October 16-18, 2024. Rebecca Rudicell, PhD, Translational Program Management, Takeda, Stephen Smith, Senior Program Director, Oncology, Corcept Therapeutics will lead this session, exploring the crucial role of strategic prioritization. Learn how to align resources with high-potential trials for efficient use of time, budget, and expertise. Ready to optimize your clinical trial portfolio? Register now: https://lnkd.in/dmKigmrk #PPM #Boston #ClinicalTrials #ResourceAllocation

𝐕𝐞𝐥𝐨𝐜𝐢𝐭𝐲 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐅𝐨𝐨𝐭𝐩𝐫𝐢𝐧𝐭 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞 𝐰𝐢𝐭𝐡 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐒𝐢𝐭𝐞 𝐍𝐞𝐭𝐰𝐨𝐫𝐤𝐬 London-based Contract Research Organization (CRO), Velocity Clinical Research, has expanded its presence in Europe by acquiring three clinical site networks in Poland and Germany. The acquired sites include KO-MED Centra Kliniczne in Poland and the Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB Gesundheitsforschung Lübeck in Germany. This expansion adds seven new clinical sites to Velocity's global portfolio. The acquisition of KO-MED marks Velocity's entry into oncology research, which constitutes a significant portion of global clinical trials. The Pulmonary Research Institute has a history of over 300 studies with a focus on bronchial asthma, bronchiectasis, and pulmonary fibrosis. The financial details of the transactions were not disclosed. Velocity Clinical Research now has nearly 100 locations worldwide with access to over 220 principal investigators and 1 million patients. #cro #clinicalresearch #networkexpansion https://lnkd.in/dCZX_BYa

Learn more about the power of liquid Biopses to revolucionize cancer care and bring us to closer to the ideal of personilized medicine approaches! These are great workshops!